Staphylococcus Aureus Infection Clinical Trial
Official title:
Community-Acquired Methicillin Resistant Staphylococcus Aureus (CA-MRSA) Vaginal and Nasal Colonization in Pregnant Women and Frequency of CA-MRSA Infections in Previously Healthy Term and Near-Term Neonates
Background:
Community acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) is an emerging
pathogen of the 21st century whose incidence as a cause of local and invasive infections has
significantly increased, especially in previously healthy term and near term newborns. The
etiology of the increasing incidence of infection in previously healthy term and near-term
newborns remains unclear.
Hypothesis:
1. The incidence of previously healthy newborns infected with CA-MRSA skin & soft tissue
(SSTI) and invasive infections is higher in those born to mothers colonized with
CA-MRSA.
2. Pregnant women colonized with CA-MRSA are at higher risk for post-partum infection with
this organism.
Specific Aims:
1. To determine the incidence of nasal and vaginal colonization with CA-MRSA in pregnant
women and determine the genetic similarities of these strains.
2. To study CA-MRSA transmission dynamics and evaluate the incidence of SSTI and invasive
infections in newborns born to S. aureus colonized mothers.
3. To study the efficacy of attempted decolonization in CA-MRSA colonized mothers in
decreasing the incidence of transmission and development of SSTI and invasive
infections in their infants during the first month of life.
Potential Impact:
Understanding the epidemiology of the transmission dynamics of CA-MRSA in previously healthy
newborns will provide important information to support the development of strategies aimed
at the interruption of transmission and prevention of infection caused by CA-MRSA in
newborns, as well as in pregnant women. This will also allow for the development of
infection control strategies to prevent the spread of this organism among post-partum units
and nurseries.
Background:
Community acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) is an emerging
pathogen of the 21st century whose incidence as a cause of local and invasive infections has
significantly increased, especially in previously healthy term and near term neonates where
it may be associated with high morbidity and mortality(1, 2, 3). The etiology for this
increase remains unclear, but may be a consequence of perinatal or postnatal acquisition via
maternal transmission through skin, breast milk, or vaginal colonization(4).
The major goals of our study are: to determine the incidence of pregnant women who are
colonized with CA-MRSA, gain a better understanding of the transmission dynamics of this
organism between the mother and the newborn infant, and to develop strategies for the
prevention of transmission, spread and infection with this organism in both these
populations.
This staged study is a collaborative effort between investigators from the Children's
Memorial Hospital Division of Infectious Diseases, Northwestern Memorial Hospital Department
of Obstetrics and Gynecology, and the Northwestern Memorial Hospital Division of Infectious
Diseases. Collaboration across multiple specialties provides strength to the study by
allowing the investigators to address multiple issues that are pertinent to both the care of
pregnant mothers and newborn infants in the inpatient and outpatient setting.
Hypothesis:
1. The incidence of previously healthy term and near-term neonates infected with CA-MRSA
skin & soft tissue (SSTI) and invasive infections is higher in those born to mothers
vaginally and/or nasally colonized with CA-MRSA and, 2. Pregnant women vaginally and/or
nasally colonized with CA-MRSA are at higher risk for post-partum infection with this
organism.
Specific Aims:
1. To determine the incidence of nasal and vaginal colonization with CA-MRSA in pregnant
women and determine the clonality of these strains.
2. To study CA-MRSA transmission dynamics and evaluate the incidence of SSTI and invasive
infections in term and near-term newborns born to S. aureus vaginal and/or nasal
colonized mothers.
3. To study the efficacy of attempted decolonization in CA-MRSA colonized mothers in
decreasing the incidence of transmission and development of SSTI and invasive
infections in their infants during the first month of life.
Methods:
1. Vaginal and anterior nasal cultures will be obtained prospectively over several months
from pregnant women who obtain their prenatal care through Obstetrical practices at
Prentice Women's Hospital and Maternity Center of Northwestern Memorial Hospital during
the time of GBS screening at 34-36 weeks gestation. Together, these practices account
for 300-500 deliveries per month.
2. Cultures will be plated on blood agar and incubated at 37oC for 48 hours. S. aureus
strains will be identified by colony morphology and latex agglutination. MRSA isolates
will be identified by PCR or latex agglutination for penicillin binding protein 2a by
detecting the mecA gene and clonality by PFGE. PCR testing will then be used to
identify strains carrying the Panton-Valentine Leukocidin gene as a marker of
virulence.
3. In a prospective case-control cohort study, newborns born to CA-MRSA colonized mothers
will have anterior nares cultures for S. aureus obtained at birth and followed for the
development of SSTI and invasive infections for one month. Samples positive for MRSA
will be tested for similarities to maternal isolates through methods described above.
The newborn incidence of MRSA infection will be compared between those born to
non-colonized mothers and those born to colonized mothers.
4. In further stages of this study, women found to be nasally and/or vaginally colonized
with CA-MRSA will be randomized to receive postpartum, either: 1) attempted
decolonization with intranasal mupirocin with or without diluted chlorhexidine or
Clorox baths or, 2) no intervention.
Potential Impact:
Understanding the epidemiology of the transmission dynamics of CA-MRSA in previously healthy
neonates will provide important information to support the development of strategies aimed
at the interruption of transmission and prevention of infection caused by CA-MRSA in this
patient population, as well as in pregnant women. This will also allow for the development
of infection control strategies in the hospital setting to prevent the spread of this
organism among post-partum units and nurseries.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04210505 -
Nasal Decolonization of Dialysis Patients Noses
|
Phase 4 | |
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Completed |
NCT02804711 -
A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
|
Phase 1 | |
Completed |
NCT02282605 -
Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects
|
Phase 1/Phase 2 | |
Recruiting |
NCT06319235 -
Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT06317688 -
Effectiveness of Highly Purified Anhydrous (HPA) Lanolin Versus Extra-Virgin Coconut Oil in Preventing Subacute Lactation Mastitis
|
Phase 1 | |
Withdrawn |
NCT02741869 -
Photodisinfection for the Decolonization of Staphylococcus Aureus in Hemodialysis Patients
|
N/A | |
Completed |
NCT03966040 -
A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
|
Phase 1 | |
Completed |
NCT04803708 -
Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers
|
Phase 1/Phase 2 | |
Recruiting |
NCT05117398 -
Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus
|
Phase 3 | |
Not yet recruiting |
NCT06456424 -
Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection
|
Phase 1/Phase 2 | |
Completed |
NCT02820883 -
A Study of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
|
Phase 0 | |
Active, not recruiting |
NCT01879761 -
Immune Resolution After Staphylococcus Aureus Bacteremia
|
||
Completed |
NCT01375621 -
Livestock Contact and MRSA in Rural Areas
|
||
Completed |
NCT04503252 -
Probability of Target Attainment With Standard Intermittent Bolus Administration of Cefazolin in Patients With Complicated Infections Caused by Staphylococcus Aureus
|
||
Recruiting |
NCT06368856 -
Pharmacology of Mupirocin in Nasal Application in Healthy Volunteers: Monocentric Study
|
Phase 1 | |
Not yet recruiting |
NCT05899140 -
Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial
|
Phase 4 | |
Completed |
NCT01792804 -
Staphylococcus Aureus Bacteremia Antibiotic Treatment Options
|
Phase 3 | |
Enrolling by invitation |
NCT04897971 -
Serum Based Diagnosis of and Monitoring of Infection Recovery in Orthopedic Spine Implant Infections
|
||
Completed |
NCT00572910 -
A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED)
|
Phase 2 |